Browse the evidence

Incretin analogs (liraglutide, semaglutide, and tirzepatide) are effective for weight management in adults without diabetes, with percent weight loss ranging from 5.7% to 20.9%.

Healthcare providers can consider prescribing these agents for weight management in overweight or obese patients without diabetes.

GLP-1 receptor agonists provide glycemic and complication-risk reduction benefits for individuals with type 2 diabetes.

Practitioners can consider GLP-1 receptor agonists as effective treatment options for managing glycemic levels and reducing complications in type 2 diabetes patients.

Semaglutide leads to significantly higher overall weight loss compared to placebo and most other comparison treatments.

Semaglutide may be a viable option for practitioners looking to support weight loss in obese and overweight patients.

CagriSema is being marketed as a safe and potentially superior medication to lower both Hemoglobin A1c and body weight.

Practitioners may consider CagriSema as a treatment option for patients needing glycemic control and weight management.

Weight-loss medications, especially incretin mimetics, are effective for short- and long-term treatment of obesity-related hypertension.

Practitioners may consider prescribing incretin mimetics for effective management of obesity-related hypertension.

Orlistat and Liraglutide are currently available medication options for long-term obesity treatment in Germany.

Clinicians can prescribe Orlistat or Liraglutide for patients needing long-term obesity management.

Semaglutide shows effective weight reduction and HbA1c lowering in Type 2 Diabetes treatment.

Semaglutide can be recommended for patients with Type 2 Diabetes who also need to lose weight.

Glucagon-like peptide-1 receptor agonists have shown potential in treating obesity and reducing the risk of type 2 diabetes.

Healthcare providers may consider glucagon-like peptide-1 receptor agonists as a treatment option for obesity and diabetes risk reduction.

Treatment proposals for obesity must be individualized according to phenotyping.

Tailoring obesity treatment plans to individual profiles can enhance effectiveness.

Glucagon-like peptide-1 receptor agonists induce substantial and durable weight loss and improve obesity-related gastrointestinal outcomes.

Practitioners can consider GLP-1 receptor agonists as effective treatments for weight management and gastrointestinal health.

GLP-1 receptor agonists have shown remarkable weight loss potential comparable to bariatric interventions.

GLP-1 receptor agonists may be a viable non-invasive alternative for weight loss in some patients.

Tirzepatide offers superior glycemic control and weight reduction compared to conventional GLP-1 receptor agonists.

Practitioners may consider Tirzepatide as a more effective option for managing glycemic control and weight in patients with T2DM.

The weight loss program reduced insomnia symptoms by -17.1 ± 7.4 (p = 0.03; d = -0.30) compared to the waitlist control group.

Weight loss interventions may be beneficial for improving sleep quality in cancer survivors.

Semaglutide is endorsed for obesity treatment following its FDA approval for type 2 diabetes.

Health practitioners can consider semaglutide as a treatment option for obesity.

Lifestyle modifications are often the first-line intervention for improving hormonal imbalances and menstrual cycles in women with PCOS.

Clinicians should consider lifestyle modifications as a primary strategy in managing PCOS.

Tirzepatide 10 mg was associated with a reduction in predicted 10-year risk of type 2 diabetes from 5.3% to 1.2%.

Practitioners may consider tirzepatide as an effective intervention for reducing diabetes risk in overweight or obese patients.

Tirzepatide 15 mg was associated with a reduction in predicted 10-year risk of type 2 diabetes from 4.9% to 1.0%.

Practitioners may consider tirzepatide as an effective intervention for reducing diabetes risk in overweight or obese patients.

Two-thirds of respondents reported reduced appetite, food cravings, or body weight.

Practitioners can expect that a significant portion of patients may experience appetite reduction and weight loss with Ozempic.

Semaglutide (Wegovy) has demonstrated unprecedented efficacy in weight reduction, glycaemic control, and cardiovascular protection.

Semaglutide may be a highly effective treatment option for obesity and type 2 diabetes.

Subcutaneous semaglutide 0.5 mg and subcutaneous liraglutide 3 mg are effective treatments for reducing weight among people with obesity in a real-world scenario after 3 months.

Both semaglutide and liraglutide can be considered effective options for weight management in clinical practice.

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) provide potent weight reduction among persons with overweight/obesity and show cardiovascular benefits.

GLP-1 RAs may be considered as a therapeutic option for weight management in patients with HIV and obesity.

Semaglutide is endorsed as a secondary treatment for improving glycemic control in type 2 diabetes mellitus (T2DM).

Practitioners can consider semaglutide as a secondary option for patients with T2DM to improve blood sugar control.

Semaglutide is being investigated for its potential in combating obesity.

Practitioners should stay informed about the potential use of semaglutide for obesity management.

Semaglutide can help regulate blood sugar levels and decrease long-term health complications related to diabetes.

Practitioners can use semaglutide to manage blood sugar levels and reduce diabetes-related complications.